Search clinical trials for: 5-HT3 inhibitor

Total 68976 results

Cairo University

Completed

Cardioprotective Effect of Ketamine-dexmeditomidine Versus Fentanyl-midazolam in Open Heart Surgery in Pediatrics

Anesthesia

Egypt
Tata Memorial Centre

Withdrawn

Effect of TIVA Propofol vs Sevoflurane Anaesthetic on Serum Biomarkers and on PBMCs in Breast Cancer Surgery

Female Breast Cancer

India
Ain Shams University

Completed

Lumbar Epidural Analgesia Versus Local Anesthesia With Dexmedetomidine Infusion in Endoscopic Lumbar Discectomy

Lumbar Disc Herniation

Egypt
Boehringer Ingelheim

Withdrawn

Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice

Hypertension

Japan
Sanofi

Completed

A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol

Type 2 Diabetes Mellitus

United States
Beth Israel Deaconess Medical Center

Completed

The PATHFINDER Study: A Feasibility Trial (PATHFINDER)

Coronary Artery Disease | Delirium

United States
National Taiwan University Hospital

Unknown

Rate Control in Patients With Atrial Fibrillation (RaP-AF)

Atrial Fibrillation | Rate Control | Cardiopulmonary Exercise Test

Taiwan
Hadassah Medical Organization

Unknown

Gait Characteristics Following a Fall

Motor Impairments | Orthopaedic Injuries | Neurological Conditions

Israel
Chosun University Hospital

Completed

Effect of Dexmedetomidine on Recovery Profiles of Elderly Patients (CSUHAPM)

Anesthesia | Elderly Patients | Emergence From Anesthesia | Effects of Dexmedetomidine | Recovery From Anesthesia

Korea, Republic of
Medical University of Vienna

Completed

Mechanisms of Choroidal Blood Flow Changes During Dark/Light Transitions

Ocular Physiology | Regional Blood Flow

Austria
Radboud University Medical Center
Hoffmann-La Roche

Completed

Mycophenolate Mofetil in Membranous Nephropathy

Glomerulonephritis, Membranous

Netherlands
Washington University School of Medicine

Active, not recruiting

Closed Loop Acoustic Stimulation During Sedation With Dexmedetomidine (CLASS-D)

Sleep | Sedation Complication

United States
University of South Florida
National Cancer Institute (NCI)

Terminated

Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy

Unspecified Childhood Solid Tumor, Protocol Specific | Nausea | Vomiting

United States, Puerto Rico
Ain Shams University

Completed

Comparison Between Adjuvants Added to Bupivacaine in Adductor Canal Block

Anesthesia

Egypt
Mansoura University

Active, not recruiting

Different Modalities of Analgesia in Open Heart Surgeries in Mansoura University

Coronary Artery Disease | Pain, Postoperative | Pain, Acute | Valve Disease, Heart

Egypt
National Cancer Institute (NCI)

Active, not recruiting

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor

United States
National Institute of Allergy and Infectious Diseases...
Rho Federal Systems Division, Inc.; Autoimmunity Centers of Excellence

Completed

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Systemic Lupus Erythematosus (SLE) | Multiple Sclerosis (MS) | Rheumatoid Arthritis (RA) | Juvenile Dermatomyositis (JDM) | Juvenile Idiopathic Arthritis (JIA) | Pemphigus Vulgaris | Systemic Sclerosis (SSc) | Pediatric SLE | Pediatric-Onset Multiple Sclerosis (POMS)

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma

Plasma Cell Myeloma | Plasma Cell Leukemia in Remission

United States
Rashmi Verma, MD
National Cancer Institute (NCI)

Recruiting

Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Adenocarcinoma | Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
Medical University of Lodz

Recruiting

The Effect of Preoperative Oral Dexamethasone Supplementation on the Outcome of Thyroidectomised Patients. (Dexa)

Postoperative Complications | Postoperative Pain | Vitamin D Deficiency | Hypocalcemia | Hypoparathyroidism Postprocedural | Postoperative Nausea | Voice Hoarseness

Poland
Fred Hutchinson Cancer Center
medac GmbH

Recruiting

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Acute Myeloid Leukemia | Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Mantle Cell Lymphoma | Lymphoplasmacytic Lymphoma | Anaplastic Large Cell Lymphoma | Acute Leukemia | Myelodysplastic Syndrome | Prolymphocytic Leukemia | Refractory... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Recurrent... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

Refractory Plasma Cell Myeloma | Plasmacytoma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Recurrent Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Refractory Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Lymphoma | Clonal Cytopenia of Undetermined Significance | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis

Secondary Myelofibrosis

United States
M.D. Anderson Cancer Center
Incyte Corporation

Active, not recruiting

Itacitinib for the Prevention of Graft Versus Host Disease

Hematologic and Lymphocytic Disorder

United States
National Cancer Institute (NCI)
Radiation Therapy Oncology Group

Completed

Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IIA Cervical Cancer AJCC v7 | Stage IIB Cervical Cancer AJCC v6 and v7 | Stage III Cervical Cancer AJCC v6 and v7 | Stage IB Cervical Cancer AJCC v6 and v7

United States, Canada
National Cancer Institute (NCI)

Recruiting

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

Recurrent Adult Lymphoblastic Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA

United States, Canada, Saudi Arabia, Puerto Rico, Australia, New Zealand
Joseph Tuscano
National Cancer Institute (NCI); ADC Therapeutics S.A.

Recruiting

Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Double-Expressor Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

United States
OHSU Knight Cancer Institute
AbbVie; Oregon Health and Science University

Recruiting

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

B Acute Lymphoblastic Leukemia | Recurrent B Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Mixed Phenotype Acute Leukemia

United States
University of Washington
National Cancer Institute (NCI)

Completed

Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma

Grade 3b Follicular Lymphoma | Stage III Follicular Lymphoma | Composite Lymphoma | Stage I Diffuse Large B-Cell Lymphoma | Stage I Follicular Lymphoma | Stage II Diffuse Large B-Cell Lymphoma | Stage II Follicular Lymphoma | Stage III Diffuse Large B-Cell Lymphoma | Stage IV Diffuse Large B-Cell Lymphoma and other conditions

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Active, not recruiting

Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment

B-Cell Non-Hodgkin Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Anaplastic Large Cell Lymphoma, ALK-Positive | Adult T-Cell Leukemia/Lymphoma | Angioimmunoblastic T-Cell Lymphoma | Hepatosplenic T-Cell Lymphoma | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Enteropathy-Associated T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | Anaplastic... and other conditions

United States, Canada
Tang-Du Hospital

Unknown

Effects of Dexmedetomidine on Postoperative Cognitive Dysfunction During One-lung Ventilation in Elder Patients

Postoperative Confusion
National Cancer Institute (NCI)

Recruiting

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Recurrent Langerhans Cell Histiocytosis | Refractory Langerhans Cell Histiocytosis

United States, Canada
Emory University
National Cancer Institute (NCI)

Not yet recruiting

Cabozantinib in Combination With Atezolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Adrenal Cortical Carcinoma | Stage III Adrenal Cortex Carcinoma | Stage IV Adrenal Cortex Carcinoma AJCC v8 | Unresectable Adrenal Cortex Carcinoma | Locally Advanced Adrenal Cortex Carcinoma

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors

Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

Desmoplastic Melanoma

United States
National Cancer Institute (NCI)

Withdrawn

Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

Urothelial Carcinoma | Renal Pelvis and Ureter Urothelial Carcinoma | Bladder Carcinoma | Stage III Bladder Cancer AJCC v8 | Stage IVA Bladder Cancer AJCC v8 | Bladder Urothelial Carcinoma | Muscle Invasive Bladder Carcinoma | Stage II Bladder Cancer AJCC v8

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery

Resectable Pancreatic Carcinoma | Stage I Pancreatic Cancer AJCC v6 and v7 | Stage IA Pancreatic Cancer AJCC v6 and v7 | Stage IB Pancreatic Cancer AJCC v6 and v7 | Stage II Pancreatic Cancer AJCC v6 and v7 | Stage IIA Pancreatic Cancer AJCC v6 and v7 | Stage IIB Pancreatic Cancer AJCC v6 and v7

United States
Baylor College of Medicine

Withdrawn

Trial- Dysphagia From ETT or GI Endoscopy

Dysphagia | Respiratory Complications
Pfizer
UCB Pharma

Completed

Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma

Lymphoma, B-Cell

Korea, Republic of, Canada, Belgium, Singapore, United States, Hong Kong, Japan, United Kingdom, France
National Institute of Allergy and Infectious Diseases...
Immune Tolerance Network (ITN)

Terminated

Belatacept to Prevent Organ Rejection in Kidney Transplant Patients (BESTT)

Renal Transplant

United States
National Cancer Institute (NCI)

Not yet recruiting

Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-Wildtype
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma

United States
University of Sao Paulo General Hospital

Recruiting

Ketamine Versus Magnesium Sulfate in the Time and Awakening Quality of General Anesthesia.

Awakening, Post-Anesthesia Delayed

Brazil
Camillo Ricordi and Jay Skyler
Diabetes Research Institute Foundation

Not yet recruiting

Diabetes Islet Preservation Immune Treatment (DIPIT)

Autoimmune Diseases | Diabetes Mellitus | Hypoglycemia | Diabetes Mellitus, Type 1

United States
National Cancer Institute (NCI)

Suspended

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

Diffuse Glioma | Secondary Glioblastoma | Glioblastoma, IDH-Wildtype | Astrocytoma, IDH-Mutant, Grade 4

United States, Puerto Rico

Search clinical trials for: 5-HT3 inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations